Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study.

Autor: De Souza S; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK., Kahol de Jong J; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK., Perone Y; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK., Shetty S; National Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK., Qurashi M; National Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK., Vithayathil M; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK., Shah T; National Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK., Ross P; Department of Oncology, Guys' & St. Thomas' and King's College Hospitals, London SE1 9RT, UK., Temperley L; Department of Oncology, Guys' & St. Thomas' and King's College Hospitals, London SE1 9RT, UK., Yip VS; Barts and the London HPB Centre, Royal London Hospital, Whitechapel E1 1BB, UK., Banerjee A; Barts and the London HPB Centre, Royal London Hospital, Whitechapel E1 1BB, UK., Bettinger D; Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine, Freiburg University Medical Center, University of Freiburg, 79098 Freiburg, Germany., Sturm L; Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine, Freiburg University Medical Center, University of Freiburg, 79098 Freiburg, Germany., Reeves HL; Newcastle University Clinical and Translational Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK., Geh D; Newcastle University Clinical and Translational Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK., Orr J; Department of Hepatology, Bristol Royal Infirmary, Bristol BS2 8HW, UK., Allen B; Department of Hepatology, Bristol Royal Infirmary, Bristol BS2 8HW, UK., Jones RP; School of Cancer Studies, Institute of Translational Medicine, University of Liverpool, Liverpool L3 5TR, UK., Sharma R; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Jun 27; Vol. 15 (13). Date of Electronic Publication: 2023 Jun 27.
DOI: 10.3390/cancers15133378
Abstrakt: Introduction: The COVID-19 pandemic has caused severe disruption of healthcare services worldwide and interrupted patients' access to essential services. During the first lockdown, many healthcare services were shut to all but emergencies. In this study, we aimed to determine the immediate and long-term indirect impact of COVID-19 health services utilisation on hepatocellular cancer (HCC) outcomes.
Methods: A prospective cohort study was conducted from 1 March 2020 until 30 June 2020, correlating to the first wave of the COVID-19 pandemic. Patients were enrolled from tertiary hospitals in the UK and Germany with dedicated HCC management services. All patients with current or past HCC who were discussed at a multidisciplinary meeting (MDM) were identified. Any delay to treatment (DTT) and the effect on survival at one year were reported.
Results: The median time to receipt of therapy following MDM discussion was 49 days. Patients with Barcelona Clinic Liver Cancer (BCLC) stages-A/B disease were more likely to experience DTT. Significant delays across all treatments for HCC were observed, but delay was most marked for those undergoing curative therapies. Even though severe delays were observed in curative HCC treatments, this did not translate into reduced survival in patients.
Conclusion: Interruption of routine healthcare services because of the COVID-19 pandemic caused severe delays in HCC treatment. However, DTT did not translate to reduced survival. Longer follow is important given the delay in therapy in those receiving curative therapy.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje